Is Tirzepatide a GLP-3? The Triple Agonist Mechanism Explained
Understanding how Tirzepatide's receptor targets produce its therapeutic effects.
Tirzepatide's Drug Class: What It Means
Tirzepatide is a once-weekly injectable that simultaneously activates GIP and GLP-1 receptors. GLP-1 activation suppresses appetite, slows gastric emptying, and enhances insulin secretion. GIP activation amplifies insulin response and may improve lipid metabolism and fat storage patterns. The dual mechanism produces greater weight loss than GLP-1-only drugs like semaglutide.
Frequently Asked Questions
What drug class is Tirzepatide?
Tirzepatide is a GIP/GLP-1 Dual Receptor Agonist. Tirzepatide is a once-weekly injectable that simultaneously activates GIP and GLP-1 receptors. GLP-1 activation suppresses appetite, slows gastric emptying, and enhances insulin secretion. GIP activation amplifies insulin response and may improve lipid metabolism and fat storage patterns. The dual mechanism produces greater weight loss than GLP-1-only drugs like semaglutide.
How does Tirzepatide work for weight loss?
Tirzepatide causes weight loss through its receptor activity. Tirzepatide is a once-weekly injectable that simultaneously activates GIP and GLP-1 receptors. GLP-1 activation suppresses appetite, slows gastric emptying, and enhances insulin secretion. GIP activation amplifies insulin response and may improve lipid metabolism and fat storage patterns. The dual mechanism produces greater weight loss than GLP-1-only drugs like semaglutide.
Exploring Retatrutide Access?
See how patients are accessing retatrutide through physician-supervised telehealth and compounding pharmacies.
Not FDA approved. Access requires physician oversight.
Affiliate links — we may earn a commission at no cost to you.